4D-710 in Adult Patients With Cystic Fibrosis

Summary

This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.

Timeline

Start

2022-03-29

Primary completion

2027-06

Completion

2031-06

Publications

• Calton MA, Croze RH, Sullivan TH, Collins SA, Tucker S, Whittlesey KJ, Kim DH, Nye JA, Beliakoff G, Quezada M, Burns C, Schmitt C, Klein A, Jia V, Kovacs L, Lauko D, Yoh K, Nguyen K, Barglow K, Gonzales J, Khoday D, Mason T, Delaria K, Bashour K, Kotterman M, Schaffer D, Song A, Francis P, Taylor-Cousar JL, Kirn D. Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease. Am J Respir Cell Mol Biol. 2026 Jul 1;74(7):837-846. doi: 10.1165/rcmb.2025-0243MA.

Drugs

Indications